Anupam Rasayan India Ltd
Anupam Rasayan India Q2 Results 2026 (FY27): Revenue ₹821 Cr, PAT ₹65 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #20 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
Anupam Rasayan India Ltd Q2 FY27 key numbers
- Revenue
- Q2 FY27 standalone revenue: ₹413 Cr, 23% QoQ growth.
As stated in Anupam Rasayan India Ltd's Q2 FY27 investor presentation · published 6 Nov 2026. Reported figures, not investment advice.
Based on Anupam Rasayan India Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 consolidated revenue: ₹821 Cr, up 12% YoY (₹731 Cr in Q2 FY26 including one-off sales of ₹180 Cr). Q2 FY27 Consolidated EBITDA: ₹202 crore, up 41% YoY.
From Anupam Rasayan India Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.
How did Anupam Rasayan India's revenue grow in the September 2026 quarter?
- Q2 FY27 consolidated revenue: ₹821 Cr, up 12% YoY (₹731 Cr in Q2 FY26 including one-off sales of ₹180 Cr)
- Q2 FY27 standalone revenue: ₹413 Cr, 23% QoQ growth
- H1 FY27 consolidated revenue: ₹1,489 Cr, 21% YoY growth (₹1,230 Cr in H1 FY26)
- H1 FY27 standalone revenue: ₹748 Cr, 2% YoY growth excluding one-off sales
- Volume capacity highlighted: Total specialty chemicals capacity >2,00,000 MT (Group proforma FY26)
2 more points from Anupam Rasayan India Ltd's call on revenue
Create a free account to keep reading this call
What happened to Anupam Rasayan India's margins in Q2 FY27?
See what Anupam Rasayan India Ltd said on profitability & margins — free account, 30 seconds.
What capex is Anupam Rasayan India planning?
- Commissioned Solar Power Plant of 5.4 MW at Bharuch in 2023 (Phase III - Acceleration).
- Commissioned Hybrid Power Plant of 9.6 MW in 2024 (Phase III - Acceleration).
- Acquired U.S.-based Jayhawk Fine Chemicals Corporation and controlling stake in Bliss GVS Pharma Limited by 2026.
- Acquired equity shares in Tanfac Industries through preferential issue and controlling stake acquired in 2022.
- Expansion includes 14 manufacturing plants (including Tanfac, Jayhawk, Bliss GVS Pharma).
- Installed capacity: Specialty Chemicals - 2,00,000+ MT; Pharmaceutical Formulation - 4,800+ million units.
2 more points from Anupam Rasayan India Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Anupam Rasayan India raising money or cutting debt?
See what Anupam Rasayan India Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Anupam Rasayan India's order book?
- The investor presentation reports a strong order book totaling ₹17,496 crores across 17 LOIs/contracts.
- The orders span multiple sectors, including Life Science, Other Specialty Chemicals, and Battery Chemicals.
- Contract tenors range from 1 to 10 years, with various statuses such as "Commercialized" and "To be commercialized" in future fiscal years (FY27, FY28).
- Significant recent LOIs/contracts include:
- ₹3,000 Cr LOI with Elementium (Battery Chemical) to be commercialized in FY27 (5 years)
- ₹2,186 Cr LOI with a Japanese Chemical Company (Life Science) to be commercialized in FY28 (5 years)
- ₹2,850 Cr LOI with BASEQUEVOLT, S.A (Other Specialty Chemical) to be commercialized in FY27 (10 years)
2 more points from Anupam Rasayan India Ltd's call on order book
Create a free account to keep reading this call
Anupam Rasayan India Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹636 Cr, net profit ₹56 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anupam Rasayan India Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries (Q2 FY27)
One Sudarshan: ₹ 868 Cr, up 22.0% YoY (Q2 FY26: ₹ 712 Cr) [Page 20] . Key investor presentation takeaways from Sudarshan Chemical Industries Ltd's Q2 FY27 inves
- Laxmi Organic (Q2 FY27)
Q2FY27 Revenue from operations: INR 10,827 Mn, up 54.7% year-on-year (Q2FY26: INR 6,997 Mn) . Key investor presentation takeaways from Laxmi Organic Industries
- Kiri Industries Ltd (Q2 FY27)
Q2-FY27 Consolidated Revenue from Operations: INR 2,882 million, up 48.1% YoY from INR 1,946 million in Q2-FY26 (Page 13). Key investor presentation takeaways f
- Excel Industries (Q2 FY27)
Q2 FY27 Revenue from Operations (Standalone): ₹274.6 Cr, up 1.6% YoY (Page 11) . Key investor presentation takeaways from Excel Industries Ltd's Q2 FY27 investo
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anupam Rasayan India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anupam Rasayan India Ltd Q2 FY27 results?
Q2 FY27 consolidated revenue: ₹821 Cr, up 12% YoY (₹731 Cr in Q2 FY26 including one-off sales of ₹180 Cr). Q2 FY27 Consolidated EBITDA: ₹202 crore, up 41% YoY.
What is Anupam Rasayan India Ltd share price analysis?
Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 75.0 with a market cap of ₹13,113 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anupam Rasayan India Ltd planning capital expenditure?
Commissioned Solar Power Plant of 5.4 MW at Bharuch in 2023 (Phase III - Acceleration).
Keep Anupam Rasayan India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.